Targeting high-risk MYC-overexpressed osteosarcoma with an Aurora kinase inhibitor:--results from a pilot umbrella trial.
Tian K, Jiang Y, Sun M, Lv Y, Fan J, Sun C, Zhu Y, Yu Y, Qiang X, Peng P, Wu F, Zhao W, Zuo D, Wang H, Wang C, Sun W, Wang J, Cai Z, Hua Y.
Tian K, et al. Among authors: lv y.
NPJ Precis Oncol. 2025 Dec 10. doi: 10.1038/s41698-025-01219-7. Online ahead of print.
NPJ Precis Oncol. 2025.
PMID: 41372533
Free article.